Published in final edited form as:

Org Biomol Chem. 2017 October 31; 15(42): 8883–8887. doi:10.1039/c7ob02391j.

A cryptophane-based “turn-on” ^{129}Xe NMR biosensor for monitoring calmodulin

Brittany A. Riggle, Mara L. Greenberg, Yanfei Wang, Rebecca F. Wissner, Serge D. Zemerov, E. James Petersson, and Ivan J. Dmochowski*

Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, USA

Abstract

We present the first cryptophane-based “turn-on” ^{129}Xe NMR biosensor, employing a peptide-functionalized cryptophane to monitor the activation of calmodulin (CaM) protein in solution. In the absence of CaM binding, interaction between the peptide and cryptophane completely suppresses the hyperpolarized ^{129}Xe -cryptophane NMR signal. Biosensor binding to Ca^{2+} -activated CaM produces the expected ^{129}Xe -cryptophane NMR signal.

TOC image

A cryptophane-peptide conjugate identifies activated calmodulin in solution, with appearance of Xe-129 NMR signal.

Calmodulin (CaM) is a small (17 kDa) calcium-binding messenger protein that is expressed in all eukaryotic cells. CaM transduces calcium signals to mediate a wide variety of processes from muscle contraction and metabolism to memory formation, inflammation, and immune response.¹ CaM binds four Ca^{2+} ions, which activates binding to a variety of helix-forming peptide sequences with μM to nM K_D values.² Comparison of crystallographic and solution NMR structures of calcium-free (apo)³ and calcium-bound (holo)⁴ CaM revealed that Ca^{2+} binding induces conformational changes necessary for peptide binding.⁵ When Ca^{2+} -CaM binds to a cognate peptide, it undergoes a second dramatic conformational change (Fig. 1), which has been probed using many spectroscopic techniques.^{2, 6} Here, we investigate the potential for using sensitive hyperpolarized (hp) ^{129}Xe NMR spectroscopy to detect active CaM in solution.

* ivandmo@sas.upenn.edu; Tel: +1-215-898-6459.

†Electronic Supplementary Information (ESI) available: Descriptions of biosensor synthesis, purification, and characterization; protein preparation; biosensor-protein interaction.

Our sensor design builds on previous work characterizing CaM complexes with cyclic nucleotide-activated cation channels (OCNCs) that function to mediate olfactory and visual signal transduction.⁷ It was determined that CaM binds to a 26-amino acid N-terminal portion of rat, bovine, and fish transmembrane OCNCs and that Ca²⁺ is necessary for substrate binding.^{7–8} The CaM binding motif in this and other peptides is characterized by several attributes, namely, a basic amphiphilic structure, the ability to form a helix, and two hydrophobic “anchor residues”, typically 10–14 amino acids apart.^{7, 9} The original 26 amino acid sequence was pared down to a 17-mer truncated peptide that retained the ability to bind CaM, which we here call FRRIAR (Scheme 1).^{6a} This truncated peptide retains two aromatic amino acids characteristic of CaM binding motifs: Phe¹ and Trp¹⁴ in a canonical 1–14 binding mode.^{7, 9b}

The Dmochowski laboratory and others have developed hyperpolarized (hp) ¹²⁹Xe NMR biosensors for detecting proteins, oligonucleotides, and metal ions in solution.¹⁰ Less investigated is the potential for studying protein-protein interactions using ¹²⁹Xe NMR spectroscopy.¹¹ Xenon-129 has a spin-1/2 nucleus and isotopic abundance of 26.4%.¹² Non-Boltzmann distributions of spins can be achieved in a hyperpolarization process termed spin-exchange optical pumping (SEOP). This characteristic, coupled with the lack of endogenous xenon *in vivo*, results in the potential for very large signal-to-noise ratios, compared to traditional proton MRI. Due to its polarizable electron cloud, xenon exhibits appreciable affinity for small-molecule hosts such as cryptophane derivatives, and to a lesser extent, cucurbit[6]uril.¹³ Cryptophanes can be made water-soluble and provide a hydrophobic cavity with internal volume roughly double that of Xe ($D = 4.3 \text{ \AA}$, $V \approx 40 \text{ \AA}^3$).^{13f–h, 14} Our laboratory^{11, 15} and others¹⁶ have designed cryptophane-xenon biosensors targeted to specific biomarkers indicated in cancer, including integrin^{11b} and folate receptors,^{15b} EGFR,^{16h} mIgM,¹⁶ⁱ MMP-7,¹⁷ and carbonic anhydrase.^{15a} Additionally, studies have demonstrated the use of xenon biosensors to target live cells.^{15c, 18} In these prior examples, Xe binding to cryptophane biosensors produced a specific hp ¹²⁹Xe NMR chemical shift, which shifted downfield when bound to protein analyte.

Herein, we demonstrate a novel turn-on detection approach where hp ¹²⁹Xe-cryptophane NMR signal is absent until a protein-peptide interaction occurs. We demonstrate a binary (ON/OFF) ¹²⁹Xe signal in the presence and absence of Ca²⁺-CaM (Fig. 1). Building on our earlier synthetic work, we conjugated the FRRIAR CaM-binding peptide and two water-solubilizing moieties to our tripropargyl cryptophane host molecule. Scheme 1 shows the synthesis of the FRRIAR peptide-trifunctionalized, ultrasensitive cryptophane (FRRIAR-TUC) **5**, the details of which are provided in the ESI. Briefly, the synthesis of tripropargyl cryptophane **1** was performed in six non-linear steps with a yield for the five linear steps of 9.9%.^{15c} Azido-FRRIAR peptide **2** was prepared with standard Fmoc-based synthetic methods. A single peptide was attached to the cryptophane via copper(I)-catalyzed [3+2] azide-alkyne cycloaddition (CuAAC) to form **3** after a 3 h reaction.¹⁹ Conjugation of a single peptide to the cryptophane was achieved by controlling reaction stoichiometry (1:0.8 cryptophane to peptide). Analysis by reverse-phase high performance liquid chromatography (HPLC) indicated complete consumption of azido-peptide and formation of compound **3** and was confirmed by matrix-assisted laser desorption mass spectrometry (MALDI-MS, Figs. S1

and S2). The triazole-hexyl spacer keeps the peptide in close proximity to the cryptophane-bound ^{129}Xe nucleus while minimizing potential steric clashes with CaM upon peptide binding. A solubilizing linker, 3-azidopropionic acid **4**, was synthesized in one step from the commercially available β -propiolactone (see ESI).^{11b, 15a} After consumption of **2**, as confirmed by HPLC (Fig. S1), **4** was added to the crude reaction containing **3** without further addition of copper catalyst. Starting from tripropargyl cryptophane **1**, FRRIAR-TUC **5** was isolated in ~70% yield after HPLC purification (Fig. S3) and its identity was confirmed by MALDI-MS (Fig. S4).

To ensure that FRRIAR-TUC binds holo CaM in the expected 1:1 stoichiometry, we employed a native gel-shift assay previously demonstrated by Liu *et al.*⁷ In this assay, protein migration is retarded after binding peptide, relative to CaM alone. This assay confirmed that the FRRIAR-TUC biosensor binds in a 1:1 stoichiometry at 10 μM holo CaM concentration in CaM binding buffer: 10 mM HEPES, 1 mM CaCl_2 , pH 7.2 with 1% DMSO (Fig. 2 and Figs. S5 and S6).⁷ To investigate whether the biosensor binds to calmodulin in the same calcium-dependent fashion as peptide alone, apo CaM was prepared (see procedure in ESI) and characterized by thermal denaturation using electronic circular dichroism (ECD) spectroscopy (Table S2, Fig. S7). Holo CaM is thermostable with a melting temperature (T_m) greater than 90 $^\circ\text{C}$, and can be easily differentiated from the apo protein for which the reported T_m is approximately 50 $^\circ\text{C}$, depending on buffer conditions.²⁰ Native gel analysis verified that FRRIAR-TUC, like FRRIAR peptide alone, cannot bind CaM in the absence of Ca^{2+} (Fig. 2, lanes 3 & 5; in 10 mM HEPES, pH 7.2, 1% DMSO). Finally, we investigated if non-specific interactions between CaM and the biosensor could promote protein conformational change. The assay was repeated with CaM and a water-soluble tris(triazole propionic acid) cryptophane-A derivative lacking the FRRIAR peptide (TTPC, structure shown in Fig. S11). Lack of gel shift was observed (Fig. S8), confirming that cryptophane alone does not generate CaM conformational change.

Although NMR⁷⁻⁸ and X-ray crystallographic²¹ studies indicate that the FRRIAR peptide is helical upon CaM binding (Fig. 1), ECD studies demonstrate that the peptide is less folded (Fig. 3, red trace) when free in solution. Interestingly, after conjugating FRRIAR to cryptophane, the peptide helicity (Fig. 3, blue trace) increased from 11% to 37% (Table S1 and Fig. S9). Because racemic cryptophane does not contribute to the ECD signal, we conclude that conjugation to the cryptophane promotes FRRIAR peptide folding, through cryptophane-peptide interactions. This provides evidence of interaction between cryptophane and conjugated peptide. These data are consistent with previous data showing that cryptophane promotes helicity in a helix-forming peptide, likely through cryptophane/peptide π -stacking interactions.^{15c}

The FRRIAR peptide contains a single tryptophan residue (Trp^{14}) towards the C-terminus that we hypothesized should provide a useful probe of peptide – protein binding, as well as changes in peptide-cryptophane interaction. Fluorescence binding studies ($\lambda_{\text{ex}} = 295 \text{ nm}$) with FRRIAR demonstrated a hypsochromic shift and increased Trp emission intensity upon binding holo CaM (Fig. 4a). The emission maximum for the FRRIAR peptide decreased from 352 nm to 332 nm with increasing concentrations of CaM protein. This is a blue shift of 20 nm. In contrast, the emission maximum for FRRIAR-TUC is 328 nm in the absence of

CaM, with a slight additional blue-shift of 3 nm and similar trend of increasing intensity upon CaM titration (Fig. 4b). The observation of Trp fluorescence quenching in FRRIAR-TUC is consistent with cryptophane-peptide interaction, and, more specifically, the Trp residue interacting with the hydrophobic cryptophane moiety. Upon CaM binding, the cryptophane quenching of FRRIAR is reduced. Notably, the cryptophane also fluoresces ($\lambda_{\text{max}} = 317$ nm) upon 295-nm excitation, which contributes to the observed blue-shifted emission spectrum for the cryptophane-FRRIAR peptide conjugate. For comparison, the emission spectrum of TTPC is shown in Fig. 4b (black trace) and agrees with our previous studies.^{13g, 17}

Finally, hp ^{129}Xe NMR spectroscopy was employed to further investigate the FRRIAR-TUC/CaM interaction. Notably, FRRIAR-TUC alone gave no hp ^{129}Xe -cryptophane NMR signal at a concentration of 70 μM in CaM binding buffer; only hp ^{129}Xe @ H_2O resonance was observed (Fig. 5a). At this concentration (determined by UV-vis spectroscopy Fig. S10), the ^{129}Xe -cryptophane signal has been easily observable in prior constructs studied in our laboratory.^{11b, 15} Additionally, TTPC at the same concentration and in the same buffer conditions generates a strong ^{129}Xe NMR signal (Fig. S12). Upon addition of equimolar holo CaM, FRRIAR-TUC in CaM binding buffer, produced a strong ^{129}Xe NMR signal corresponding to cryptophane-CaM complex formation (Fig. 5b). The two bound peaks (65.9, 67.6 ppm) were assigned to diastereomers, which are formed when racemic cryptophane is conjugated to the chiral peptide. Diastereomeric ^{129}Xe NMR peaks have been observed previously for peptide-cryptophane conjugates as well as for xenon biosensors bound to protein active sites.^{15a, 16a} No hp ^{129}Xe NMR signal was observed for FRRIAR-TUC in the presence of apo CaM (Fig. S13), as the FRRIAR/CaM interaction is much weaker in the absence of calcium (as confirmed by gel electrophoresis, Fig. 2). Additionally, there was no observed signal when hp ^{129}Xe NMR spectroscopy was performed on holo CaM in the presence of FRRIAR alone (Fig. S14). These experiments demonstrate the first example of a “turn-on” cryptophane-based xenon NMR biosensor, which results from the binding of FRRIAR-TUC to Ca^{2+} -loaded CaM.

Our ECD and Trp fluorescence data indicate significant cryptophane-peptide interaction, as has been previously demonstrated for related xenon biosensors with a pendant peptide incorporating aromatic residues.^{15c, 17} Such interactions, particularly when aromatic residues are positioned near the cryptophane, are likely to favor less xenon-accessible cryptophane conformations resulting in an “OFF” signal from the biosensor. We hypothesize that upon FRRIAR binding to holo CaM—which has high affinity for the 17-mer peptide anchored by conserved Phe¹ and Trp¹⁴ residues—cryptophane-FRRIAR interactions are decreased, making the cryptophane more accessible to xenon binding.⁷ The result is that xenon biosensor signal is turned “ON”.

In conclusion, we report a straightforward synthesis for the first “turn-on” cryptophane-xenon biosensor, which was used to detect Ca^{2+} -bound CaM protein. This so-called turn-on effect improves signal-to-noise, especially in scenarios where there are multiple biosensors with both “free” and “bound” signals. The observation of signal only in the presence of target analyte will also facilitate ultrasensitive detection using hyperpolarized chemical exchange saturation transfer (Hyper-CEST) NMR techniques.^{16e} For example, large-

spectral-width, high-power pulses that increase detection sensitivity can be employed without interfering signal from untargeted biosensor(s). Thus, this work highlights a potential new paradigm for cryptophane-based xenon biosensors. Future studies will help to elucidate the nature of peptide-cryptophane interactions that can produce the “OFF” state.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by National Institutes of Health (NIH R01-GM097478). EJP acknowledges support for CaM projects through the National Science Foundation (NSF CHE-1150351). We thank Dr. Rakesh Kohli for assistance with MALDI-MS (NSF MRI-0820996). We thank Drs. George Furst and Jun Gu for assistance with NMR spectroscopy. We also thank the University of Pennsylvania Biological Chemistry Resource Center for automated peptide synthesis supported by UPenn Laboratory for Research on the Structure of Matter (NSF MRSEC DMR 0520020, 1120901). RFW thanks the NIH for funding through the Chemistry-Biology Interface Training Program (T32 GM07133). We thank Dr. Jacob Goldberg for help with data analysis.

Notes and references

- Vetter SW, Leclerc E. *Eur J Biochem.* 2003; 270:404–414. [PubMed: 12542690]
- Ye Y, Liu X, Xu G, Liu M, Li C. *Angew Chem Int Ed Engl.* 2015; 54:5328–5330. [PubMed: 25753548]
- (a) Schumacher MA, Crum M, Miller MC. *Structure.* 2004; 12:849–860. [PubMed: 15130477] (b) Kuboniwa H, Tjandra N, Grzesiek S, Ren H, Klee CB, Bax A. *Nat Struct Biol.* 1995; 2:768–776. [PubMed: 7552748]
- Chattopadhyaya R, Meador WE, Means AR, Quijcho FA. *J Mol Biol.* 1992; 228:1177–1192. [PubMed: 1474585]
- Zhang M, Tanaka T, Ikura M. *Nat Struct Biol.* 1995; 2:758–767. [PubMed: 7552747]
- (a) Goldberg JM, Wissner RF, Klein AM, Petersson EJ. *Chem Commun.* 2012; 48:1550–1552. (b) Wissner RF, Batjargal S, Fadzen CM, Petersson EJ. *J Am Chem Soc.* 2013; 135:6529–6540. [PubMed: 23594264] (c) He YF, Haque MM, Stuehr DJ, Lu HP. *Proc Natl Acad Sci USA.* 2015; 112:11835–11840. [PubMed: 26311846] (d) Jensen D, Reynolds N, Yang YP, Shakyia S, Wang ZQ, Stuehr DJ, Wei CC. *BMC Biochem.* 2015; 16:6. [PubMed: 25888318] (e) Jones EM, Balakrishnan G, Squier TC, Spiro TG. *Protein Sci.* 2014; 23:1094–1101. [PubMed: 24895328] (f) Liu S, Sui Y, Guo K, Yin Z, Gao X. *Nanoscale Res Lett.* 2012; 7:433–440. [PubMed: 22856352]
- Liu M, Chen TY, Ahamed B, Li J, Yau KW. *Science.* 1994; 266:1348–1354. [PubMed: 7526466]
- Contessa GM, Orsale M, Melino S, Torre V, Paci M, Desideri A, Cicero DO. *J Biomol NMR.* 2005; 31:185–199. [PubMed: 15803393]
- (a) Yamniuk AP, Vogel HJ. *Mol Biotechnol.* 2004; 27:33–57. [PubMed: 15122046] (b) Tidow H, Nissen P. *FEBS J.* 2013; 280:5551–5565. [PubMed: 23601118]
- Kotera N, Tassali N, Leonce E, Boutin C, Berthault P, Brotin T, Dutasta JP, Delacour L, Traore T, Buisson DA, Taran F, Coudert S, Rousseau B. *Angew Chem Int Ed Engl.* 2012; 51:4100–4103. [PubMed: 22411775]
- (a) Seward GK, Wei Q, Dmochowski IJ. *Bioconjugate Chem.* 2008; 19:2129–2135. (b) Seward GK, Bai Y, Khan NS, Dmochowski I. *Chem Sci.* 2011; 2:1103–1110. [PubMed: 25364495]
- De Laeter JR, Bohlke JK, De Bievre P, Hidaka H, Peiser HS, Rosman KJR, Taylor PDP. *Pure Appl Chem.* 2003; 75:683–800.
- (a) Wang Y, Dmochowski IJ. *Chem Commun.* 2015; 51:8982–8985. (b) Finbloom JA, Slack CC, Bruns CJ, Jeong K, Wemmer DE, Pines A, Francis MB. *Chem Commun.* 2016; 52:3119–3122. (c) Hane FT, Li T, Smylie P, Pellizzari RM, Plata JA, DeBoef B, Albert MS. *Sci Rep.* 2017; 7(d) Kunth M, Witte C, Hennig A, Schroder L. *Chem Sci.* 2015; 6:6069–6075. (e) Taratula O, Hill PA, Bai YB, Khan NS, Dmochowski IJ. *Org Lett.* 2011; 13:1414–1417. [PubMed: 21332141] (f)

- Jacobson DR, Khan NS, Colle R, Fitzgerald R, Laureano-Perez L, Bai Y, Dmochowski IJ. *Proc Natl Acad Sci USA*. 2011; 108:10969–10973. [PubMed: 21690357] (g) Hill PA, Wei Q, Eckenhoff RG, Dmochowski IJ. *J Am Chem Soc*. 2007; 129:11662–11662.(h) Hill PA, Wei Q, Troxler T, Dmochowski IJ. *J Am Chem Soc*. 2009; 131:3069–3077. [PubMed: 19239271] (i) Fairchild RM, Joseph AI, Holman KT, Fogarty HA, Brotin T, Dutasta JP, Boutin C, Huber G, Berthault P. *J Am Chem Soc*. 2010; 132:15505–15507. [PubMed: 20958059] (j) Huber G, Beguin L, Desvaux H, Brotin T, Fogarty HA, Dutasta JP, Berthault P. *J Phys Chem A*. 2008; 112:11363–11372. [PubMed: 18925727]
14. Taratula O, Hill PA, Khan NS, Carroll PJ, Dmochowski IJ. *Nat Commun*. 2010; 1
15. (a) Chambers JM, Hill PA, Aaron JA, Han ZH, Christianson DW, Kuzma NN, Dmochowski IJ. *J Am Chem Soc*. 2009; 131:563–569. [PubMed: 19140795] (b) Khan NS, Riggle BA, Seward GK, Bai Y, Dmochowski IJ. *Bioconjugate Chem*. 2015; 26:101–109.(c) Riggle BA, Wang Y, Dmochowski IJ. *J Am Chem Soc*. 2015; 137:5542–5548. [PubMed: 25848822]
16. (a) Spence MM, Rubin SM, Dimitrov IE, Ruiz EJ, Wemmer DE, Pines A, Yao SQ, Tian F, Schultz PG. *Proc Natl Acad Sci USA*. 2001; 98:10654–10657. [PubMed: 11535830] (b) Meldrum T, Seim KL, Bajaj VS, Palaniappan KK, Wu W, Francis MB, Wemmer DE, Pines A. *J Am Chem Soc*. 2010; 132:5936–5937. [PubMed: 20392049] (c) Spence MM, Ruiz EJ, Rubin SM, Lowery TJ, Winssinger N, Schultz PG, Wemmer DE, Pines A. *J Am Chem Soc*. 2004; 126:15287–15294. [PubMed: 15548026] (d) Boutin C, Stopin A, Lenda F, Brotin T, Dutasta JP, Jamin N, Sanson A, Boulard Y, Leteurtre F, Huber G, Bogaert-Buchmann A, Tassali N, Desvaux H, Carriere M, Berthault P. *Bioorg Med Chem*. 2011; 19:4135–4143. [PubMed: 21605977] (e) Schröder L, Lowery TJ, Hilty C, Wemmer DE, Pines A. *Science*. 2006; 314:446–449. [PubMed: 17053143] (f) Klippel S, Dopfert J, Jayapaul J, Kunth M, Rossella F, Schnurr M, Witte C, Freund C, Schröder L. *Angew Chem Int Ed Engl*. 2014; 53:493–496. [PubMed: 24307424] (g) Klippel S, Freund C, Schröder L. *Nano Lett*. 2014; 14:5721–5726. [PubMed: 25247378] (h) Palaniappan KK, Ramirez RM, Bajaj VS, Wemmer DE, Pines A, Francis MB. *Angew Chem Int Ed Engl*. 2013; 52:4849–4853. [PubMed: 23554263] (i) Jeong K, Netirojjanakul C, Munch HK, Sun J, Finbloom JA, Wemmer DE, Pines A, Francis MB. *Bioconjugate Chem*. 2016; 27:1796–1801.
17. Wei Q, Seward GK, Hill PA, Patton B, Dimitrov IE, Kuzma NN, Dmochowski IJ. *J Am Chem Soc*. 2006; 128:13274–13283. [PubMed: 17017809]
18. (a) Witte C, Martos V, Rose HM, Reinke S, Klippel S, Schröder L, Hackenberger CPR. *Angew Chem Int Ed Engl*. 2015; 54:2806–2810. [PubMed: 25676513] (b) Schnurr M, Sydow K, Rose HM, Dathe M, Schröder L. *Adv Healthc Mater*. 2014(c) Rose HM, Witte C, Rossella F, Klippel S, Freund C, Schröder L. *Proc Natl Acad Sci USA*. 2014; 111:11697–11702. [PubMed: 25071165]
19. (a) Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. *Angew Chem Int Ed Engl*. 2002; 41:2596–2599. [PubMed: 12203546] (b) Tornøe CW, Christensen C, Meldal M. *J Org Chem*. 2002; 67:3057–3064. [PubMed: 11975567]
20. (a) Brzeska H, Venyaminov S, Grabarek Z, Drabikowski W. *FEBS Lett*. 1983; 153:169–173. [PubMed: 6825857] (b) Gibrat G, Assairi L, Craescu CT, Hoa GHB, Loew D, Lombard B, Blouquit L, Bellissent-Funel MC. *Biochimica Et Biophysica Acta-Proteins and Proteomics*. 2012; 1824:1097–1106.(c) Masino L, Martin SR, Bayley PM. *Protein Sci*. 2000; 9:1519–1529. [PubMed: 10975573] (d) Protasevich I, Ranjbar B, Lobachov V, Makarov A, Gilli R, Briand C, Lafitte D, Haiech J. *Biochemistry*. 1997; 36:2017–2024. [PubMed: 9047299] (e) Sorensen BR, Shea MA. *Biochemistry*. 1998; 37:4244–4253. [PubMed: 9521747]
21. Meador WE, Means AR, Quijcho FA. *Science*. 1992; 257:1251–1255. [PubMed: 1519061]

Figure 1.

a. Native conformational change of calmodulin with the addition of 4 calcium ions and subsequent folding in the presence of FRRIAR peptide. b. "Turn-on" ^{129}Xe NMR signal resulting from FRRIAR-TUC biosensor binding to holo CaM. CaM binding peptide structure taken from PDB 1SY9. Image generated in PyMOL (Delano Scientific, LLC; South San Francisco, CA USA)

Figure 2.

Native gel-shift assay with samples of 10 μ M CaM only or 10 μ M CaM plus either 10 μ M FRRIAR peptide or 10 μ M FRRIAR-TUC biosensor in 10 mM HEPES, $\pm$ 1 mM CaCl_2 , pH 7.2. 1) Apo CaM only; 2) Holo CaM only; 3) Apo CaM + FRRIAR peptide; 4) Holo CaM + FRRIAR peptide; 5) Apo CaM + FRRIAR-TUC; and 6) Holo CaM + FRRIAR-TUC.

Figure 3.
Circular dichroism comparison of FRRIAR peptide (red trace, 30 μ M) vs. FRRIAR-TUC biosensor (blue trace, 10 μ M) in 1:1 acetonitrile to water.

Figure 4.

Calmodulin binding monitored by Trp fluorescence for a. FRRIAR peptide (30 μM) with varying concentrations of CaM protein (0, 7.5, 15, 22.5, or 30 μM in 10 mM HEPES, 1 mM CaCl₂, pH 7.2) and; b. FRRIAR-TUC (30 μM) with varying concentrations of CaM protein (0, 7.5, 15, 22.5, or 30 μM in 10 mM HEPES, 1 mM CaCl₂, pH 7.2). Water-soluble cryptophane TTPC (15 μM in 1 mM PBS).

Figure 5.

FRRIAR-TUC alone and in the presence of apo CaM resulted in no hp ^{129}Xe NMR signal (a); CaM bound to FRRIAR-TUC resulted in two distinct ^{129}Xe NMR resonances (b). NMR performed in 10 mM HEPES, 1 mM CaCl_2 , pH 7.2 with 1% DMSO. $^{129}\text{Xe}_{\text{aq}}$ peak shown at 192.8 ppm. CaM binding peptide structure taken from PDB 1SY9. Image generated in PyMOL (Delano Scientific, LLC; South San Francisco, CA USA).

Scheme 1.

Synthesis of FRRIAR peptide conjugated to trisubstituted, ultrasensitive cryptophane (FRRIAR-TUC). a. **1** (1 eq), **2** (0.8 eq), CuBr (2 eq), TBTA (3 eq), 3 h; **3** (crude), **4** (10 eq), 12 h.